Loading...
XNAS
IPSC
Market cap51mUSD
Jun 12, Last price  
0.60USD
1D
-1.01%
1Q
0.62%
IPO
-97.61%
Name

Century Therapeutics Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
7.85
EPS
Div Yield, %
Shrs. gr., 5y
7.48%
Rev. gr., 5y
%
Revenues
7m
+194.81%
0005,199,0002,235,0006,589,000
Net income
-127m
L-7.40%
-245,979,000-54,660,000-95,824,000-130,932,000-136,673,000-126,566,000
CFO
-110m
L+24.66%
-16,168,000-41,269,000-89,002,00014,052,000-88,348,000-110,135,000

Profile

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPO date
Jun 17, 2021
Employees
163
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
6,589
194.81%
2,235
-57.01%
5,199
 
Cost of revenue
140,399
140,460
149,101
Unusual Expense (Income)
NOPBT
(133,810)
(138,225)
(143,902)
NOPBT Margin
Operating Taxes
1,790
1,881
91
Tax Rate
NOPAT
(135,600)
(140,106)
(143,993)
Net income
(126,566)
-7.40%
(136,673)
4.38%
(130,932)
36.64%
Dividends
Dividend yield
Proceeds from repurchase of equity
74,563
516
27,158
BB yield
-93.87%
-0.26%
-9.17%
Debt
Debt current
1,513
6,977
Long-term debt
97,920
93,316
81,610
Deferred revenue
111,381
110,834
Other long-term liabilities
8,738
56
718
Net debt
(122,190)
(167,005)
(278,765)
Cash flow
Cash from operating activities
(110,135)
(88,348)
14,052
CAPEX
(13,736)
(30,604)
Cash from investing activities
47,482
61,132
(13,128)
Cash from financing activities
74,563
(9,725)
27,158
FCF
(134,366)
(120,457)
(185,902)
Balance
Cash
189,292
172,738
315,498
Long term investments
30,818
89,096
51,854
Excess cash
219,781
261,722
367,092
Stockholders' equity
(782,004)
(655,657)
(521,554)
Invested Capital
1,001,064
1,000,015
985,258
ROIC
ROCE
EV
Common stock shares outstanding
78,649
59,314
57,756
Price
1.01
-69.58%
3.32
-35.28%
5.13
-67.65%
Market cap
79,435
-59.66%
196,924
-33.54%
296,287
-66.04%
EV
(42,755)
29,919
17,522
EBITDA
(120,506)
(125,181)
(135,462)
EV/EBITDA
0.35
Interest
540
1,105
Interest/NOPBT